Virusight Diagnostic nominated for Best Innovation for COVID-19 Pandemic Response & Recovery

Virusight Diagnostic, a world leader in using artificial intelligence software for pathogens diagnosis using spectral technology, has been nominated for ‘Best Innovation for COVID-19 Pandemic Response & Recovery’ at this year’s Global Mobile Awards (GLOMO Awards) by the GSMA, organiser of MWC Barcelona – the world’s most influential event for the connectivity industry.

Virusight’s recognition at MWC Barcelona is an eventful start of a break-through year for the company as it continues to build commercial success across multiple industries globally, increase headcount to accommodate surging demand and drive product innovation through highly focused research and development programmes.


Industry recognition for innovation in COVID-19 response and recovery

Virusight was established as a joint venture of ARC at Sheba Medical Center in Israel and Newsight Imaging, creators of innovative CMOS technology including its next-generation 3D sensors for metaverse, which will also be on display at the upcoming MWC Barcelona event.

Virusight’s innovative solution to COVID-19 enables almost real time detection and analysis of pathogens to help prevent the spread of infection. The device – SpectraLIT® – is an easily portable, low-cost point-of-care testing solution that uses spectrophotometry to generate high resolution spectral signatures of a sample’s contents. These signatures are interpreted using artificial intelligence within 20 seconds as either positive or negative for SARS-Cov-2, the virus that causes COVID-19.

“Clinical trials of a non-invasive oral sampling kit are well underway with preliminary results indicating high correlation with PCR,” announced Gary Cohen, CEO of Virusight. “We provide the same convenience and portability of rapid antigen tests but with a higher accuracy and the immediate identification of those who are infectious, which makes Virusight’s solution ideal for workplaces, airports, cruise lines and educational institutions.”

Virusight continues to build its commercial pipeline, striking deals with governments and industries worldwide. Cohen continued, “we have expressions of interest from several European ministries of Health and Education to implement our solution into schools and are working with one of the world’s largest cruise lines to test staff regularly and ensure the safety of their passengers. It is very exciting to have our technology recognised by GLOMO as we truly hope to make a difference and help relieve the effects of the pandemic.”


Advancing highly accurate, instant, less-intrusive testing to safely manage COVID-19

Virusight is now advancing its sample collection techniques through the availability of a pioneering saliva swab testing approach. With trials indicating high accuracy equivalent with PCR standards, this minimally invasive technique is a less intrusive and easier alternative to traditional testing methods, making it ideal to use for mass screening at public events and particularly for children. With SpectraLIT® already granted the CE Mark for the European market, Virusight also has a regulatory pipeline of approvals in process across numerous markets.

The GLOMO Awards ceremony will be held in MWC Barcelona at 12 – 1 pm (CET) Wednesday, March 2nd, 2022. The event will also be streamed online via MyMWC and publicly on Mobile World Live TV.


About Virusight Diagnostic

Virusight Diagnostic a subsidiary of Newsight Imaging along with a major shareholder incorporating ARC the innovation arm of Sheba Hospital, the largest hospital in Israel and the Middle East, recognised by Newsweek magazine as one of the Top 10 Hospitals in the World. Virusight is developing revolutionary COVID-19 rapid-testing solutions powered by AI, based on Newsight Imaging’s spectral analysis technology. The technology allows for an immediate, affordable, and portable solution that detects different pathogens including SARS-CoV-2 and could also support the detection of mutations. Learn more at